Candidate gene-environment interactions in breast cancer. by Fletcher, Olivia & Dudbridge, Frank
Fletcher, O; Dudbridge, F (2014) Candidate gene-environment inter-
actions in breast cancer. Bmc Medicine, 12. ISSN 1741-7015 DOI:
10.1186/s12916-014-0195-1
Downloaded from: http://researchonline.lshtm.ac.uk/2058771/
DOI: 10.1186/s12916-014-0195-1
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
COMMENTARY Open Access
Candidate gene-environment interactions in
breast cancer
Olivia Fletcher1,2* and Frank Dudbridge3
Abstract
Gene-environment interactions have the potential to shed light on biological processes leading to disease, identify
individuals for whom risk factors are most relevant, and improve the accuracy of epidemiological risk models.
We review the progress that has been made in investigating gene-environment interactions in the field of breast
cancer. Although several large-scale analyses have been carried out, only a few significant interactions have been
reported. One of these, an interaction between CASP8-rs1045485 and alcohol consumption has been replicated, but
others have not, including LSP1- rs3817198 and parity, and 1p11.2-rs11249433 and ever being parous. False positive
interactions may arise if the gene and environment are correlated and the causal variant is less frequent than the
tag SNP. We conclude that while much progress has been made in this area it is still too soon to tell whether
gene-environment interactions will fulfil their promise. Before we can make this assessment we will need to
replicate (or refute) the reported interactions, identify the causal variants that underlie tag-SNP associations and
validate the next generation of epidemiological risk models.
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Background
Epidemiological studies have provided consistent evi-
dence of associations between environmental (predomin-
antly lifestyle and reproductive) factors and subsequent
risk of breast cancer (BC). More recently, genome-wide
association studies (GWAS) have identified more than
70 single nucleotide polymorphisms (SNPs) that influ-
ence breast cancer risk [1]. Detecting a gene-environment
(GxE) interaction between a SNP and an environmental
risk factor has the potential to shed light on the biological
process leading to disease, identify women for whom these
risk factors are most relevant, and improve the accuracy
of epidemiological risk models [2]. A comprehensive re-
view summarising the rationale for and the challenges of
studying GxE interactions advocated a range of measures
including supporting new and larger prospective studies,
the reporting of stratified analyses as supplementary ma-
terial and pre-planned analyses coordinated across mul-
tiple studies [2]. In this commentary we review progress in
investigating GxE interactions in the field of BC. We
define GxE interaction as the modification of the effect of
a genetic risk factor by an environmental factor, assessed
statistically by testing the effects of gene and environ-
ment for departure from additivity, on an appropriate
scale (usually the log or logit in disease studies). We focus
on GxE interactions between common SNPs and estab-
lished risk factors for BC (Table 1), discuss the implica-
tions of testing marker SNPs rather than the underlying
causal variants that they tag and consider whether GxE
studies have fulfilled their potential for illuminating dis-
ease processes or predicting risk.
GxE interactions between previously reported SNPs and
established risk factors for BC
The first large (that is, at least 5,000 cases and 5,000
controls) GxE study of this type was carried out within
the Million Women Study [3]. In this analysis of 7,610
cases and 10,196 controls investigating potential GxE in-
teractions between 12 SNPs and 10 established risk factors
for BC there were no GxE interactions that were signi-
ficant after adjusting for multiple testing. The most sig-
nificant GxE interaction was between CASP8-rs1045485
and alcohol consumption (unadjusted P = 0.003). Since the
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publication of this report, there have been four further
analyses of this type (Table 2), two from the Breast Cancer
Association Consortium (BCAC) [4,5] and two from the
Breast and Prostate Cancer Cohort Consortium (BPC3)
[6,7]. Only one of these, the largest (23 SNPs in 34,793
cases and 41,099 controls) [5], reported statistically signifi-
cant GxE interactions, namely between LSP1-rs3817198
and parity (number of live births), CASP8-rs1045485 and
alcohol consumption (replicating the most significant
finding in the Million Women study [3]) and 1p11.2-
rs11249433 and ever being parous. However, none of
these interactions was replicated in the largest BPC3
study (39 SNPs in 16,285 BC cases and 19,376 controls
[7]). A meta-analysis of the BCAC and BPC3 data sug-
gested a possible interaction between SLC4A7-rs4973768
and smoking status but replication of this result has not
yet been attempted.
The Shanghai Breast Cancer Genetics Study tested for
interactions using a risk score formed as the weighted
sum of genotypes from 10 SNPs [8]. This would improve
the power to detect a risk factor that has interactions
with numerous SNPs, when there is insufficient power
for the individual interactions. Although this study found
no interactions with the risk score, this approach holds
promise for identifying interacting risk factors in limited
sample sizes.
Table 1 Established risk factors assessed in GxE interaction studies
Established risk factor Travis et al. [3] Milne et al. [4] Campa et al. [6] Nickels et al. [5] Barrdahl et al. [7] Schoeps et al. [12]
Age at menarche (years) X X X X X X
Age at first birth (years) X X Xa X
Parous (% and/or number of
live births)
X X X Xa X X
Breast fed (% in parous women) X X
Menopausal status
(% post-menopausal)
X
Age at natural menopause (years) X X X
Use of oral contraceptives
(yes/no or duration)
X X X
Use of HRT (yes/no or duration) X X X Xb
Body Mass Index (kg/m2) X X X X X Xc
Height (m) X X X X X
Alcohol consumption (g per day) X X X X X
Smoking (pack-years) X X X
Family history of BC X X X
Physical activity (hours per week) X
aThe ten established risk factors reported by Nickels et al. (Table 2) counts parity and age at first live birth as a single factor; bthe 10 established risk factors
reported by Schoeps et al. (Table 2) counts combined estrogen-progesterone and estrogen only post-menopausal hormone therapy as two factors; cbody mass
index in pre- and post-menopausal women as two factors. BC, breast cancer; HRT, hormone replacement therapy.
Table 2 Details of GxE interaction studies comprising at least 5,000 cases and 5,000 controls
Reference Study SNPs ERFs Cases Controls Strongest interaction Interaction
effect size
Unadjusted P
Travis et al. [3] Million women 12 10 7,610 10,196 CASP8-rs1045485; alcohol consumptiona 1.24 0.003
Milne et al. [4] BCAC (1) 12 4 26,349 32,208 LSP1- rs3817198; parity 1.05 0.002
Campa et al. [6] BPC3 (1) 17 9 8,576 11,892 5p12-rs10941679; use of estrogen only HRT 1.22 0.0072
Nickels et al. [5] BCAC (2) 23 10 34,793 41,099 LSP1- rs3817198; parity 1.06 2.4 × 10−6
1p11.2-rs11249433; ever parous 1.16 5.3 × 10−5
CASP8-rs17468277; alcohol consumptiona 1.59 3.1 × 10−4
Barrdahl et al. [7] BPC3 (2) 39 10 16,285 19,376 6q25-rs2046210; alcohol consumptiona 1.11 0.002
Schoeps et al. [12] BCAC 71,527 10 34,475 34,786 21q22.12-rs10483028 and rs2242714;
postmenopausal BMI
0.84 3.2 × 10−5
aAlcohol consumption was defined as per additional 10 g in Travis et al. and Barrdahl et al. and as < or ≥20 g/per day by Nickels et al. BCAC, Breast Cancer
Association Consortium; BMI, body mass index; BPC3, Breast and Prostate Cancer Cohort Consortium; ERFs, established risk factors for breast cancer; HRT,
hormone replacement therapy.
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Identification of novel risk SNPs through GxE interactions
SNPs with strong interaction effects may only be detect-
able when analysing gene and environment together, so
they are missed by studies that consider SNPs in isola-
tion. Methods that model and test the main and inte-
raction effects of gene and environment jointly [9], or
exploit the power of a case-only design while retaining
robustness to possible gene environment dependence
[10,11] have been developed for these purposes. Re-
cently, several of these methods were applied to 71,527
SNPs with suggestive association with BC [12]. Interac-
tions were identified between two SNPs on 21q22.12
(rs10483028 and rs2242714) and adult body mass index
(BMI), and one in ARID1B (rs12197388) with age at me-
narche and with parity. rs12197388 was only significant
in the joint test of main and interaction effects, and the
interaction term was not significant but the two SNPs
on 21q22.12 were detected via their interactions, and
further studies of this nature may discover more inter-
actions using these novel methods.
Using tag-SNPs as proxies for an underlying causal variant
The GxE studies described above have relied on using
marker SNPs, predominantly identified through GWAS,
as proxies for the underlying causal variants. This usu-
ally leads to a loss in power to detect interactions [13].
However, if gene and environment are dependent, a
marker SNP can show an interaction even if there is no
interaction at the causal variant [14]. These ‘spurious
interactions’ tend to arise when the causal variant is rare
in comparison to the marker. This may not often be
the case, but it nevertheless warrants caution when
reporting GxE interactions. We recently studied a marker
SNP (rs10235235) associated with a reduction in urinary
levels of an estrogen metabolite [15]. In 47,346 cases and
47,569 controls in the Collaborative Oncological Gene-
environment Study (COGS) [1,16] this SNP showed (1)
association with BC risk, (2) association with age at me-
narche in controls (but not cases) and (3) an interaction in
which age at menarche modified the effect of rs10235235
on BC risk. In this example of a GxE interaction, there-
fore, the genetic risk factor (rs10235235) is dependent on
the environmental risk factor (age at menarche), which
could lead to a false positive [14]. Of the interactions
reported to date, gene-environment dependence has
been observed between LSP1-rs3817198 and parity and
21q22.12-rs10483208/rs2242714 and BMI. In cases such
as these, an interaction can only be definitively estab-
lished when all variation in the associated regions has
been identified and tested.
Conclusions
Several of the recommendations made by Hunter in 2005
[2] have been pursued: large new prospective studies
continue to be supported (for example the Breakthrough
Generations study, a long-term cohort study focused on
BC has recruited 112,049 women over the period 2003 to
2011 [17]), consortia of case–control (BCAC) and cohort
studies (BPC3) have coordinated their efforts for analyses
of data from >70,000 women and the results of stratified
analyses have been conscientiously reported in supple-
mentary tables [5,7]. However, one of the lessons of the
first generation of BC GWAS [18-20] was that the per-
allele disease odds ratios (ORs) associated with individual
tag-SNPs were much smaller than hypothesised (1.07 to
1.26). Results from the first generation of GxE analyses
suggest that the same may be true for interactions, with
the reported interaction ORs ranging from 1.06 to 1.59.
If marginal ORs of 1.07 to 1.26 require scans of several
thousand cases and several thousand controls then, de-
pending on the number of GxE interactions being tested,
only GxE studies that include tens of thousands of cases
and controls will have the power required to detect inter-
actions. It is hardly a coincidence that the first study to re-
port statistically significant GxE interactions was the first
study of this order of magnitude [5]. Of the three signifi-
cant interactions reported by Nickels and colleagues there
is replication only for CASP8-rs1045485 and alcohol con-
sumption. It is currently too soon to tell whether GxE
interactions will shed light on disease processes and im-
prove the accuracy of epidemiological risk models. Before
we can make this assessment we will need to replicate or
refute the reported interactions, identify the causal vari-
ants that underlie tag-SNP associations and validate the
next generation of epidemiological risk models.
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